Correlation Between DiaMedica Therapeutics and Bristol Myers

Can any of the company-specific risk be diversified away by investing in both DiaMedica Therapeutics and Bristol Myers at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining DiaMedica Therapeutics and Bristol Myers into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between DiaMedica Therapeutics and Bristol Myers Squibb, you can compare the effects of market volatilities on DiaMedica Therapeutics and Bristol Myers and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in DiaMedica Therapeutics with a short position of Bristol Myers. Check out your portfolio center. Please also check ongoing floating volatility patterns of DiaMedica Therapeutics and Bristol Myers.

Diversification Opportunities for DiaMedica Therapeutics and Bristol Myers

0.51

Correlation Coefficient

DiaMedica Therapeutics  Bristol Myers

Very weak diversification

The 3 months correlation between DiaMedica and Bristol is 0.51. Overlapping area represents the amount of risk that can be diversified away by holding DiaMedica Therapeutics and Bristol Myers Squibb in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Bristol Myers Squibb and DiaMedica Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on DiaMedica Therapeutics are associated (or correlated) with Bristol Myers. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Bristol Myers Squibb has no effect on the direction of DiaMedica Therapeutics i.e., DiaMedica Therapeutics and Bristol Myers go up and down completely randomly.

Pair Corralation between DiaMedica Therapeutics and Bristol Myers

Given the investment horizon of 90 days DiaMedica Therapeutics is expected to generate 2.83 times more return on investment than Bristol Myers. However, DiaMedica Therapeutics is 2.83 times more volatile than Bristol Myers Squibb. It trades about 0.09 of its potential returns per unit of risk. Bristol Myers Squibb is currently generating about 0.06 per unit of risk. If you would invest  437.00  in DiaMedica Therapeutics on October 6, 2024 and sell it today you would earn a total of  119.00  from holding DiaMedica Therapeutics or generate 27.23% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

DiaMedica Therapeutics  vs.  Bristol Myers Squibb

DiaMedica Therapeutics

Risk-Adjusted Performance

7 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in DiaMedica Therapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain basic indicators, DiaMedica Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point.

Bristol Myers Squibb

Risk-Adjusted Performance

4 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Bristol Myers Squibb are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal primary indicators, Bristol Myers may actually be approaching a critical reversion point that can send shares even higher in February 2025.

Pair Trading with DiaMedica Therapeutics and Bristol Myers

The main advantage of trading using opposite DiaMedica Therapeutics and Bristol Myers positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if DiaMedica Therapeutics position performs unexpectedly, Bristol Myers can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will offset losses from the drop in Bristol Myers' long position.

The idea behind DiaMedica Therapeutics and Bristol Myers Squibb pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.